Mycophenolate Mofetil in Nonrenal Manifestations of Systemic Lupus Erythematosus: An Observational Cohort Study

REFERENCES

1. 1.↵
   1. Mak A,
   2. Cheak AA,
   3. Tan JY,
   4. Su HC,
   5. Ho RC,
   6. Lau CS

   . Mycophenolate mofetil is as efficacious as, but safer than, cyclophosphamide in the treatment of proliferative lupus nephritis: a meta-analysis and meta-regression. Rheumatology 2009;48:944–52.

   OpenUrlAbstract/FREE Full Text
2. 2.↵
   1. Dooley MA,
   2. Jayne D,
   3. Ginzler EM,
   4. Isenberg D,
   5. Olsen NJ,
   6. Wofsy D,
   7. et al;
   8. ALMS Group

   . Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 2011;365:1886–95.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Henderson L,
   2. Masson P,
   3. Craig JC,
   4. Flanc RS,
   5. Roberts MA,
   6. Strippoli GF,
   7. et al.

   Treatment for lupus nephritis. Cochrane Database Syst Rev 2012;12:CD002922.

   OpenUrlPubMed
4. 4.↵
   1. Bertsias GK,
   2. Tektonidou M,
   3. Amoura Z,
   4. Aringer M,
   5. Bajema I,
   6. Berden JH,
   7. et al;
   8. European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association

   . Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 2012;71:1771–82.

   OpenUrlAbstract/FREE Full Text
5. 5.↵
   1. Hahn BH,
   2. McMahon MA,
   3. Wilkinson A,
   4. Wallace WD,
   5. Daikh DI,
   6. Fitzgerald JD,
   7. et al;
   8. American College of Rheumatology

   . American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res 2012;64:797–808.

   OpenUrlCrossRef
6. 6.↵
   1. Mok CC

   . Mycophenolate mofetil for non-renal manifestations of systemic lupus erythematosus: a systematic review. Scand J Rheumatol 2007;36:329–37.

   OpenUrlCrossRefPubMed
7. 7.↵
   1. Moder KG,
   2. Amin S,
   3. Mazlumzadeh M,
   4. Crowson C,
   5. Ytterberg S

   . The effect of mycophenolate mofetil on patients with active non-renal SLE. Clin Exp Rheumatol 2007;25:932.

   OpenUrlPubMed
8. 8.↵
   1. Yahya F,
   2. Jasmin R,
   3. Ng CT,
   4. Cheah TE,
   5. Sockalingam S

   . Open label randomized controlled trial assessing the efficacy of mycophenolate sodium against other conventional immunosuppressive agents in active systemic lupus erythematosus patients without renal involvement. Int J Rheum Dis 2013;16:724–30.

   OpenUrlCrossRefPubMed
9. 9.↵
   1. Ginzler EM,
   2. Wofsy D,
   3. Isenberg D,
   4. Gordon C,
   5. Lisk L,
   6. Dooley MA;
   7. ALMS Group

   . Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a multicenter, prospective, randomized, open-label, parallel group clinical trial. Arthritis Rheum 2010;62:211–21.

   OpenUrlCrossRefPubMed
10. 10.↵
    1. Hochberg MC

    . Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.

    OpenUrlCrossRefPubMed
11. 11.↵
    1. Bombardier C,
    2. Gladman DD,
    3. Urowitz MB,
    4. Caron D,
    5. Chang CH

    . Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992;35:630–40.

    OpenUrlCrossRefPubMed
12. 12.↵
    1. Villaroel MC,
    2. Hidalgo M,
    3. Jimeno A

    . Mycophenolate mofetil: an update. Drugs Today 2009;45:521–32.

    OpenUrlPubMed
13. 13.↵
    1. Pisoni CN,
    2. Sanchez FJ,
    3. Karim Y,
    4. Cuadrado MJ,
    5. D’Cruz DP,
    6. Abbs IC,
    7. et al.

    Mycophenolate mofetil in systemic lupus erythematosus: efficacy and tolerability in 86 patients. J Rheumatol 2005;32:1047–52.

    OpenUrlAbstract/FREE Full Text
14. 14.↵
    1. Lhotta K,
    2. Wurzner R,
    3. Rosenkranz AR,
    4. Beer R,
    5. Rudisch A,
    6. Neumair F,
    7. et al.

    Cerebral vasculitis in a patient with hereditary complete C4 deficiency and systemic lupus erythematosus. Lupus 2004;13:139–41.

    OpenUrlAbstract/FREE Full Text
15. 15.↵
    1. Jose J,
    2. Paulose BK,
    3. Vasuki Z,
    4. Danda D

    . Mycophenolate mofetil in neuropsychiatric systemic lupus erythematosus. Indian J Med Sci 2005;59:353–6.

    OpenUrlCrossRefPubMed
16. 16.↵
    1. Mok CC,
    2. Mak A,
    3. To CH

    . Mycophenolate mofetil for lupus related myelopathy. Ann Rheum Dis 2006;65:971–3.

    OpenUrlFREE Full Text
17. 17.↵
    1. Conti F,
    2. Ceccarelli F,
    3. Perricone C,
    4. Massaro L,
    5. Cipriano E,
    6. Pacucci VA,
    7. et al.

    Mycophenolate mofetil in systemic lupus erythematosus: results from a retrospective study in a large monocentric cohort and review of the literature. Immunol Res 2014;60:270–6.

    OpenUrlCrossRefPubMed
18. 18.↵
    1. Bertsias GK,
    2. Ioannidis JP,
    3. Aringer M,
    4. Bollen E,
    5. Bombardieri S,
    6. Bruce IN,
    7. et al.

    EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis 2010;69:2074–82.

    OpenUrlAbstract/FREE Full Text
19. 19.↵
    1. Hanly JG

    . Diagnosis and management of neuropsychiatric SLE. Nat Rev Rheumatol 2014;10:338–47.

    OpenUrlCrossRefPubMed
20. 20.↵
    1. Artifoni M,
    2. Puéchal X

    . How to treat refractory arthritis in lupus? Joint Bone Spine 2012;79:347–50.

    OpenUrlCrossRefPubMed
21. 21.↵
    1. Gammon B,
    2. Hansen C,
    3. Costner MI

    . Efficacy of mycophenolate mofetil in antimalarial-resistant cutaneous lupus erythematosus. J Am Acad Dermatol 2011;65:717–21.

    OpenUrlCrossRefPubMed
22. 22.↵
    1. Bolad W,
    2. Magder L,
    3. Petri M

    . Immunosuppressive drugs in SLE differ in their hematologic side-effects. Arthritis Rheum 2009;60 Suppl 10:282.

    OpenUrl
23. 23.↵
    1. Pego-Reigosa JM,
    2. Cobo-Ibáñez T,
    3. Calvo-Alén J,
    4. Loza-Santamaría E,
    5. Rahman A,
    6. Muñoz-Fernández S,
    7. et al.

    Efficacy and safety of nonbiologic immunosuppressants in the treatment of nonrenal systemic lupus erythematosus: a systematic review. Arthritis Care Res 2013;65:1775–85.

    OpenUrlCrossRef
24. 24.↵
    1. Levine AB,
    2. Erkan D

    . Clinical assessment and management of cytopenias in lupus patients. Curr Rheumatol Rep 2011;13:291–9.

    OpenUrlCrossRefPubMed
25. 25.↵
    1. Posalski JD,
    2. Ishimori ML,
    3. Wallace DJ,
    4. Weisman MH

    . Does mycophenolate mofetil prevent extra-renal flares in systemic lupus erythematosus? Results from an observational study of patients in a single practice treated for up to 5 years. Lupus 2009;18:516–21.

    OpenUrlAbstract/FREE Full Text